Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Dose-escalation, Pharmacokinetic and Pharmacodynamic Study of Debio 0932, a Novel Hsp90-inhibitor, Administered Orally, in Patients With Advanced Solid Tumours or Lymphoma

NCT01168752 is registered in ClinicalTrials.gov with Debiopharm International SA as lead sponsor.

NCT NCT01168752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01168752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Dose-escalation, Pharmacokinetic and Pharmacodynamic Study of Debio 0932, a Novel Hsp90-inhibitor, Administered Orally, in Patients With Advanced Solid Tumours or Lymphoma
Lead sponsor
Debiopharm International SA
Phase
Phase 1
Overall status
Completed
Start date
April 30, 2010
Completion date
April 30, 2013
Enrollment
81 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, lymphoma, neoplasms, solid tumors